A randomized trial reported less shivering with remimazolam after fetal delivery, without establishing a sedation-independent mechanism.
One hundred twenty patients having cesarean delivery under neuraxial anesthesia were assigned to remimazolam, remimazolam followed by flumazenil, or saline. Shivering occurred in 17.5%, 30.0% and 52.5%, respectively. Selected temperature, traction-response and nausea outcomes also favored the remimazolam-containing groups.
Sedation depth differed between active treatment and saline, so the study could not fully separate an independent anti-shivering action from sedation itself. Flumazenil-related comparisons do not establish one specific thermoregulatory mechanism. Administration after delivery is essential context; these findings cannot be reassigned to exposure before birth or to every obstetric population.
For an obstetric-anesthesia opinion, preserve the timing relative to delivery and the separate temperature and movement endpoints. Less observed shivering does not alone establish absence of respiratory or recovery effects. This study supports a narrowly defined postoperative observation, rather than a general claim of maternal or neonatal benefit.
Source reviewed: Effects of remimazolam on postanesthetic shivering and related clinical responses in patients underg (PMC13066202). Forensic applications above are interpretive analysis of the supplied paper.
Related reading: Cesarean Remimazolam Analysis Used Uterotonic Requirements as a Proxy.